Sonnet biotherapeutics selected for poster presentation at the 2025 aacr io conference

Princeton, n.j., feb. 18, 2025 (globe newswire) -- sonnet biotherapeutics holdings, inc. (the “company” or “sonnet”) (nasdaq: sonn), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has been accepted for poster presentation at the 2025 american association for cancer research (aacr) io conference taking place on february 23-26, 2025 at the jw marriott in los angeles, ca.
SONN Ratings Summary
SONN Quant Ranking